STAb Therapeutics

A new chapter starts at STAb Therapeutics! Last week we celebrated the kick-off meeting of our STAb-SOLID consortium to develop a new STAb-T cell immunotherapy candidate for solid tumors. This is our first public-private collaboration funded by the AGENCIA ESTATAL DE INVESTIGACIÓN. We thank our consortium partners the Hospital Universitario 12 De Octubre (H12O) and the Spanish National Cancer Research Centre (CNIO) for joining STAb Therapeutics in this exciting project, which represents a major step towards our goal of offering a novel therapy for patients with solid tumors. We want to highlight the amazing team that is making this possible, especially the contribution of Luis Alvarez-Vallina, Luis Paz-Ares Rodríguez and Belén Blanco Durango, the valuable team members at STAb Therapeutics Carolina Pola, Elena Barba Sarasua, Lucía Rivas Gómez and, of course, to the UNICA Cancer Immunotherapy Unit at Hospital 12 de Octubre CNIO - Spanish National Cancer Research Centre. You are all an integral part of this initiative ! We begin this new journey excited for all that awaits us!

A new publication in Oncoimmunology by our co-founder Luis Alvarez-Vallina and his team at UNICA Cancer Immunotherapy Unit from the Hospital 12 de Octubre and CNIO - Spanish National Cancer Research Centre. This paper showcases the development and proof-of-principle of the first dual #STAb-T therapeutic approach to improve tumor control: "Dual-targeted STAb-T cells secreting BCMA and CD19 T cell engagers for improved control of hematological cancers." This is another step forward for the development of STAb-T therapies in cancer 🚀 . At STAb Therapeutics, we are committed to generating innovative ways to redirect the immune system and provide a solution for hard-to-treat cancers. 🔬 Look at our pipeline to see where we stand for the development of STAb-T therapies in oncology. #immunotherapy #cancertherapeutics #oncology #immunooncology #celltherapy https://lnkd.in/dQgHNgd5

🎄✨ Happy Holidays from the STAb Therapeutics team!    An incredible year is coming to an end. A year full of challenges, breakthroughs and many great moments. All moving us closer to achieving our mission: to offer new hope in the fight against cancer through our STAb-T immunotherapies. 🔬 Today, we would like to thank everyone who is joining us on this exciting journey, as it will not be possible without the efforts of everyone who believes in this project. Thank you for your support in helping us progress so we can bring STAb-T therapies to patients. We say goodbye to 2024 carrying the momentum toward continued growth and improvement in 2025, always focused on the most important thing: transforming patients' lives and provide value to the oncology field.   Here's to a new year full of health, progress and shared achievements! 🥂 See you in 2025 with more enthusiasm than ever!    STAb Tx TEAM

At STAb Therapeutics, we are looking for a Research Technician in Immunotherapy and Immuno-oncology to join our team in Madrid. If you have hands-on experience in advanced laboratory techniques and want to be part of a translational project developing next generation cell therapies, this is your moment! You will be part of an innovative environment, working in close collaboration with a team of researchers dedicated to the development of cellular therapies based on our STAb platform.  Your responsabilities will be👇 🔹 Cell and tissue culture, including human lymphoid cell lines and primary T cells. 🔹 Advanced techniques such as flow cytometry, functional assays, cloning and lentiviral vector generation. 🔹 Participation in preclinical research with xenogeneic murine models. 🔹 Collaboration in the preparation of preclinical data for regulatory documentation. What are the requirements for? ✔ Professional training (VET), bachelor or master degree in Biology or Biomedical Sciences. ✔ Minimum 2 years of practical laboratory experience. ✔ Experience in key techniques: flow cytometry, functional and cytotoxicity assays, Western blot, cloning and handling of murine models. ✔ Knowledge in laboratory animal handling and related regulations. ✔ Excellent organizational and analytical skills, with proactive approach. ✔ Communication skills to work effectively in a multidisciplinary team. Send your CV and a cover letter to cpola@stabtherapeutics.com indicating “Research Technician STAb” in the subject line. Application deadline: January 15, 2025.⏳  If you are looking to be part of a mission that combines science and entrepreneurship to transform cancer treatment, we look forward to seeing you at STAb Therapeutics!

New job offer! 🚨 At STAb Therapeutics we are looking for a Senior Scientist in Immunotherapy and Immuno-oncology to join our team in Madrid. If you have experience in immunotherapy, translational research and a strong interest in advancing the development of cancer therapies, we want to meet you! You will be part of a dynamic and stimulating environment, working directly with the CEO and CSO on the development of our innovative therapies based on the STAb platform. Your responsibilities will include👇 🔹 Design and execution of research projects. 🔹 Preclinical trials in murine models. 🔹 Analysis and presentation of results at scientific congresses. 🔹 Preparation of preclinical information for regulatory documents. 🔹 Supervision of technical staff in the laboratory. What are the requirements for ? ✔ PhD in Biology, Biochemistry, Biotechnology or other related fields. ✔ 5+ years of research experience in cancer immunology or immunotherapy. ✔ Solid experience in techniques such as flow cytometry, lymphocyte functional assays, cloning, lentiviral vector generation and murine xenogeneic models. ✔ Proficiency in laboratory animal handling. ✔ Excellent communication skills. Send us your CV and a cover letter to cpola@stabtherapeutics.com indicating “Senior Scientist STAb Tx” in the subject line. Application deadline: 15 January 2025.⏳ Be part of a mission that transforms academic discoveries into real solutions for patients. Don't miss the opportunity to make a difference in the field of immunotherapy! 💥

💡 STAb Therapeutics at the 4th Foro de Inversión Deep Tech BAN! 💡 Last Friday, November 29th, we had the honor of participating in the Congreso Nacional de Científicos Emprendedores, specifically in the 4º Foro de Inversión Deep Tech BAN.  This event brought together some of the brightest minds in the scientific and technological community, all with a shared goal: turning innovation into real-world impact. 🌐✨ For STAb Therapeutics, this forum was an incredible opportunity to present our work on innovative STAb-T immunotherapies to top-level investors and experts. Sharing our disruptive approach to cancer treatment and receiving feedback from leaders in science, technology, and finance is a significant step toward our mission: improving patients’ quality of life through safer and more effective therapies. 🎗️🔬 We deeply thank Deep Tech BAN and the Congreso Nacional de Científicos Emprendedores for providing this platform for visibility and collaboration.  We are more motivated than ever to continue advancing innovation and driving meaningful transformation! 🚀

🎉 STAb Therapeutics shines at SILO Summit 2024! 🎉 Yesterday was an exciting day for STAb Therapeutics at the SILO Summit 2024, where we had the honor of participating in the Pitch Competition in front of an audience of experts, industry leaders, and investors. 🚀 We are thrilled to announce that we won the Best Pitch Award among the 10 start-ups that presented! 🏆✨ During our pitch, we showcased our groundbreaking vision in cancer immunotherapy, emphasizing how our STAb-T cell therapies are designed to deliver safer, more effective, and personalized treatments for patients. 🎗️🔬 This recognition reflects the relentless dedication of our team and the transformative potential of our innovative solutions. We deeply thank the organizers of the SILO Summit 2024 for creating such a unique platform for visibility and collaboration. We share this achievement with everyone who supports us and believes in our mission. The future of biotechnology is bright, and we are thrilled to be part of it! 🌟

STAb Therapeutics participated in the #ASEICAMED retreat organized by ASEICA - Asociación Española de Investigación sobre el Cáncer with our CEO Carolina Pola as speaker at a roundtable to convey areas of improvement to shorten the valley of death in #cancerresearch in the Spanish ecosystem. As an academic spin-off in #oncology we aim to share with others the lessons learnt along the way 💡 and to listen to those who have done this before so we can streamline our development path and successfully add value where is needed the most.  🔬 The views of all the speakers at the roundtable from the pharmaceutical industry with Maria Luz Amador from Roche and two entrepreneurs in the oncology landscape in Spain Laura Soucek and Roger Gomis provided food for thought to smooth the #innovation process in transferring new technologies from academia to cancer #patients 🚀 . Thanks to the moderator Rafael Lopez Lopez for driving the exciting discussion and engage the audience in sharing their thoughts, concerns and insights. 👇

Muchas gracias a la Fundación Universidad-Empresa por invitarnos a compartir la experiencia de STAb Therapeutics y tener la oportunidad de aprender de otros emprendedores. Apoyando siempre al talento investigador.

🎉 Today is a very special day for STAb Therapeutics! 🎉    We are very excited to announce that Luis Alvarez-Vallina, co-founder of our company, has received the Best Biomedical Publication of the Year Award at the Constant and Vital Awards, an event that was held today at the Palacio de Neptuno. 🏆    This award, given by La Sexta and AXA FOUNDATION INC, recognizes outstanding research work in the field of biomedicine. This is particularly exciting as the award is a testament of the impact of the work published in Science Translational Medicine showing the efficacy of STAb technology against #multiplemyeloma. More important, this recognition is a reflection of the team work, expertise and dedication at UNICA Cancer Immunotherapy Unit, the research laboratory led by Luis Alvarez-Vallina, which has been key in the development of our innovative biomedical STAb-T therapies.     We would like to thank laSexta, AXA Foundation, and Constantes y Vitales for this incredible recognition, which not only celebrates the effort and dedication of Luis, but also of all scientists and researchers who, like him, work tirelessly to transform health and medicine. 🧬    At StabTherapeutics we strongly support the goal pursued by Constantes y vitales to drive biomedical innovation for improving patients’ lives, bringing new therapies that make a difference in the fight against cancer.    Thank you to everyone who supports #cellimmunotherapy. This is just the beginning of many more achievements! 🌟